Abstract
Since bortezomib was approved by the US Food and Drug Administration as the first proteasome inhibitor for the treatment of multiple myeloma (MM) ten years ago, proteasome inhibition has been established as an effective MM treatment strategy. However, some limitations have been found with bortezomib-based therapies, including bortezomib resistance (both intrinsic and acquired), severe toxicities (such as peripheral neuropathy), and unsatisfied efficacy in the treatment of solid tumors. In order to overcome the shortcomings of bortezomib, researchers have investigated the involved molecular mechanisms and developed novel strategies to improve proteasome inhibitor-based therapies and patient cares. This mini hot issue will review the current advances in the status of bortezomib, clinically tested second generation proteasome inhibitors, and preclinically developed proteasome inhibitors, and summarize some cutting-edge strategies in this field, including selective targeting immunoproteasomes, 19S deubiquitinases or ubiquitin E3 ligases, and developing novel combinational therapies. While there are still many new challenges ahead, the great progress in proteasome inhibitor therapy will definitely help illuminate the bright future of MM and other cancer management.
Current Cancer Drug Targets
Title:Editorial (Thematic Issue: Recent Advances in Proteasome Inhibitor-Based Cancer Therapies)
Volume: 14 Issue: 6
Author(s): Q. Ping Dou
Affiliation:
Abstract: Since bortezomib was approved by the US Food and Drug Administration as the first proteasome inhibitor for the treatment of multiple myeloma (MM) ten years ago, proteasome inhibition has been established as an effective MM treatment strategy. However, some limitations have been found with bortezomib-based therapies, including bortezomib resistance (both intrinsic and acquired), severe toxicities (such as peripheral neuropathy), and unsatisfied efficacy in the treatment of solid tumors. In order to overcome the shortcomings of bortezomib, researchers have investigated the involved molecular mechanisms and developed novel strategies to improve proteasome inhibitor-based therapies and patient cares. This mini hot issue will review the current advances in the status of bortezomib, clinically tested second generation proteasome inhibitors, and preclinically developed proteasome inhibitors, and summarize some cutting-edge strategies in this field, including selective targeting immunoproteasomes, 19S deubiquitinases or ubiquitin E3 ligases, and developing novel combinational therapies. While there are still many new challenges ahead, the great progress in proteasome inhibitor therapy will definitely help illuminate the bright future of MM and other cancer management.
Export Options
About this article
Cite this article as:
Dou Ping Q., Editorial (Thematic Issue: Recent Advances in Proteasome Inhibitor-Based Cancer Therapies), Current Cancer Drug Targets 2014; 14 (6) . https://dx.doi.org/10.2174/1568009614666140805163018
DOI https://dx.doi.org/10.2174/1568009614666140805163018 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ganglioside GD3 as a Raft Component in Cell Death Regulation
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies - Regulatory Challenges
Current Pharmaceutical Biotechnology <i>Pulsatilla saponin</i> A Induces Apoptosis and Differentiation of Myeloma Cells
Anti-Cancer Agents in Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Editorial (Thematic Issue: Molecular Aspects of Cancer Resistance to Biological and Non- Biological Drugs and Strategies to Overcome Resistance)
Current Medicinal Chemistry Trends and Prospects of Plant Proteases in Therapeutics
Current Medicinal Chemistry New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Current Pharmaceutical Design Are Hsp90 Inhibitors Good Candidates Against Covid-19?
Current Protein & Peptide Science Reconceptualizing Adult Neurogenesis: Role for Sphingosine-1-Phosphate and Fibroblast Growth Factor-1 in Co-Ordinating Astrocyte-Neuronal Precursor Interactions
CNS & Neurological Disorders - Drug Targets Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation
Current Pharmaceutical Design Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Anti-Angiogenetic Agents from the Sea: A New Potential Preventive and Therapeutic Wave?
Anti-Cancer Agents in Medicinal Chemistry Bone Metastases Radiopharmaceuticals: An Overview
Current Radiopharmaceuticals Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors
Current Drug Targets Calcium Metabolism & Hypercalcemia in Adults
Current Medicinal Chemistry Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry